Tumaini Bundibugyo Ebola Vaccine Trial Starts in Bunia
预估日期确定性: 预估目标日期,而非确定日期来源对日期的表述有多确定:已确认、已排期、预估、已推迟或未核实。显示所有“预估”的图钉可信度 69%总体可信度: 69%该图钉的来源和参考资料对其日期的支持程度。包括来源在内的 4 份资料对图钉开始和结束时间支持程度的加权平均;资料每比最新的一份旧 180 天,权重减半显示所有可信度为 50%–74% 的图钉ClinicalTrials.gov[1] lists a start date of 2026-10-20 flagged "ESTIMATED" with status "NOT_YET_RECRUITING", and study completion of 2027-06 (estimated).
The Tumaini Phase 2/3 platform trial plans to vaccinate the contacts of confirmed Bundibugyo cases in rings around each case in Bunia, targeting 3,810 participants. Run by the University of Antwerp and INRB with CEPI and WHO, it is registered to start on 20 October 2026.